Skip to content

Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions

Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions: Observational Case Control Study in Upper Egypt

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03172650
Enrollment
120
Registered
2017-06-01
Start date
2017-07-01
Completion date
2018-09-30
Last updated
2017-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Brief summary

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (\>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver disease including viral, drug-induced, or autoimmune. Non-alcoholic fatty liver disease is a hepatic manifestation of metabolic syndrome.

Interventions

DIAGNOSTIC_TESTglomerular filtration rate

collection of blood sample 5 milliliter for calculation of glomerular filtration rate

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* All non alcoholic fatty liver disease patients evidenced by abdominal ultrasound. * Urine analysis whether normal or renal sedimentation.

Exclusion criteria

1. Alcoholic fatty liver patients. 2. patients known to have diabetes mellitus. 3. patients with other causes of liver disease as viral hepatitis, drug induced,or autoimmune. 4. patients known to have kidney disease. 5. Hypertension. 6. Hyperuricemia. 7. Impaired urea and creatinine patients.

Design outcomes

Primary

MeasureTime frameDescription
The percentage of patients with abnormal laboratory glomerular filtration rate1 daydecreased glomerular filtration rate \<60 mL/minute will be considered abnormal

Countries

Egypt

Contacts

Primary ContactMahmoud Ali, MBBCh
ans1111eg@gmail.com00201144287363

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026